CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers | GenomeWeb

 

NEW YORK (GenomeWeb) – The Cancer Research UK Manchester Institute announced today it has joined Cancer-ID, a European consortium to validate blood-based biomarkers for cancer. 

With a total budget of €14.5 million ($15.7 million), Cancer-ID is a newly created consortium funded by the Innovative Medicines Initiative. It currently has 33 members from 13 countries tasked with establishing standard protocols for and clinical validation of blood-based biomarkers, such as circulating tumor cells, cell-free tumor DNA, and microRNAs. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.